Comparative Pharmacology
Head-to-head clinical analysis: LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MAXAQUIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus MAXAQUIN.
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs MAXAQUIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby interfering with DNA replication, transcription, repair, and recombination.
500 mg or 750 mg intravenously once daily. Infusion over 60-90 minutes.
400 mg orally once daily for 5-10 days; for complicated urinary tract infections, 400 mg orally once daily for 10-14 days.
None Documented
None Documented
6-8 hours in patients with normal renal function (creatinine clearance >50 mL/min); increases to 20-48 hours in severe renal impairment (CrCl <20 mL/min); clinically relevant for dosing interval adjustment.
Terminal elimination half-life is approximately 12 hours (range 10-14 hours), supporting twice-daily dosing for systemic infections.
Renal: ~87% of dose excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5% eliminated as unchanged drug and metabolites; <4% recovered in feces.
Renal excretion of unchanged drug accounts for 70-80%; biliary/fecal elimination accounts for 20-30%.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic